AN2 Therapeutics, Inc. Investment Income, Net
AN2 Therapeutics, Inc. (ANTX) reported Investment Income, Net of $1.35 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Income Statement
us-gaap:InvestmentIncomeNet · last filed 2023-03-29
- AN2 Therapeutics, Inc. investment income, net for the quarter ending 2022-12-31 was $630.00K, a 2233.33% increase year-over-year.
- AN2 Therapeutics, Inc. investment income, net for the quarter ending 2022-09-30 was $466.00K, a 1764.00% increase year-over-year.
- AN2 Therapeutics, Inc. investment income, net for the quarter ending 2022-06-30 was $228.00K, a 1420.00% increase year-over-year.
- AN2 Therapeutics, Inc. investment income, net for the quarter ending 2022-03-31 was $27.00K, a 1250.00% increase year-over-year.
- AN2 Therapeutics, Inc. investment income, net for fiscal 2022 was $1.35M, a 1857.97% increase from fiscal 2021.
- AN2 Therapeutics, Inc. investment income, net for fiscal 2021 was $69.00K.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2022-12-31 | $630.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $1.10M derived: sum of 2 quarters · filed 2023-03-29 | $1.32M derived: sum of 3 quarters · filed 2023-03-29 | $1.35M 10-K · filed 2023-03-29 |
| 2022-09-30 | $466.00K 10-Q · filed 2022-11-09 | $694.00K derived: sum of 2 quarters · filed 2022-11-09 | $721.00K 10-Q · filed 2022-11-09 | $748.00K derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-06-30 | $228.00K 10-Q · filed 2022-08-11 | $255.00K 10-Q · filed 2022-08-11 | $282.00K derived: sum of 3 quarters · filed 2023-03-29 | $307.00K derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-03-31 | $27.00K 10-Q · filed 2022-05-10 | $54.00K derived: sum of 2 quarters · filed 2023-03-29 | $79.00K derived: sum of 3 quarters · filed 2023-03-29 | $94.00K derived: sum of 4 quarters · filed 2023-03-29 |
| 2021-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $52.00K derived: sum of 2 quarters · filed 2023-03-29 | $67.00K derived: sum of 3 quarters · filed 2023-03-29 | $69.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $25.00K 10-Q · filed 2022-11-09 | $40.00K derived: sum of 2 quarters · filed 2022-11-09 | $42.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $15.00K 10-Q · filed 2022-08-11 | $17.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $2.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |